Engineering a folic acid-decorated ultrasmall gemcitabine nanocarrier for breast cancer therapy: Dual targeting of tumor cells and tumor-associated macrophages.
Breast cancer
Doxorubicin
Dual targeting
Folic acid
Gemcitabine
Polymeric micelles
Tumor associated macrophages
Ultrasmall nanocarrier
Journal
Acta pharmaceutica Sinica. B
ISSN: 2211-3835
Titre abrégé: Acta Pharm Sin B
Pays: Netherlands
ID NLM: 101600560
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
10
05
2021
revised:
29
07
2021
accepted:
18
08
2021
entrez:
9
5
2022
pubmed:
10
5
2022
medline:
10
5
2022
Statut:
ppublish
Résumé
Combination of passive targeting with active targeting is a promising approach to improve the therapeutic efficacy of nanotherapy. However, most reported polymeric systems have sizes above 100 nm, which limits effective extravasation into tumors that are poorly vascularized and have dense stroma. This will, in turn, limit the overall effectiveness of the subsequent uptake by tumor cells
Identifiants
pubmed: 35530140
doi: 10.1016/j.apsb.2021.09.024
pii: S2211-3835(21)00383-X
pmc: PMC9072252
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1148-1162Subventions
Organisme : NCI NIH HHS
ID : R01 CA174305
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA219399
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA216815
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA223788
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA249649
Pays : United States
Informations de copyright
© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
Références
Mol Pharm. 2014 Oct 6;11(10):3609-16
pubmed: 25166491
Arthritis Rheum. 2009 Jan;60(1):12-21
pubmed: 19116913
Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):1075-83
pubmed: 14575839
mBio. 2013 Jun 18;4(3):e00264-13
pubmed: 23781069
Sci Transl Med. 2018 Feb 21;10(429):
pubmed: 29467299
Biomaterials. 2016 Nov;108:44-56
pubmed: 27619239
Signal Transduct Target Ther. 2020 Jan 22;5(1):6
pubmed: 32296026
Acta Biomater. 2018 Jul 15;75:312-322
pubmed: 29885530
Biochem Pharmacol. 2021 Jul;189:114453
pubmed: 33545119
Arthritis Res Ther. 2011 Apr 08;13(2):R59
pubmed: 21477314
Oncotarget. 2017 Dec 15;9(4):4485-4495
pubmed: 29435118
Sci Transl Med. 2012 Apr 4;4(128):128ra39
pubmed: 22491949
Molecules. 2021 Feb 25;26(5):
pubmed: 33668746
Eur J Pharm Sci. 2016 Feb 15;83:184-202
pubmed: 26747018
Curr Pharm Des. 2006;12(36):4669-84
pubmed: 17168771
Int J Urol. 2017 Mar;24(3):230-235
pubmed: 28066957
Biomaterials. 2021 Feb;269:120629
pubmed: 33387938
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4628-33
pubmed: 11274375
Scand J Immunol. 2014 May;79(5):305-14
pubmed: 24521472
J Cell Physiol. 2019 Apr;234(4):4959-4969
pubmed: 30334571
Daru. 2014 Mar 06;22:30
pubmed: 24602477
Acta Biomater. 2019 May;90:300-313
pubmed: 30930305
Curr Opin Chem Biol. 2009 Jun;13(3):256-62
pubmed: 19419901
Mol Cancer Ther. 2009 Jul;8(7):1955-63
pubmed: 19567824
Nat Nanotechnol. 2011 Oct 23;6(12):815-23
pubmed: 22020122
Theranostics. 2020 Jan 1;10(3):1136-1150
pubmed: 31938056
Mol Pharm. 2018 Nov 5;15(11):5162-5173
pubmed: 30222360
Nanoscale. 2014 Sep 21;6(18):10710-6
pubmed: 25096971
Oncotarget. 2017 Mar 28;8(13):21526-21538
pubmed: 28423526
Nat Mater. 2013 Nov;12(11):958-62
pubmed: 24150413
Acta Biomater. 2016 Oct 1;43:282-291
pubmed: 27422196
J Control Release. 2003 Aug 28;91(1-2):103-13
pubmed: 12932642
Ann Oncol. 1999 Dec;10(12):1461-5
pubmed: 10643537
Cancer Res. 1999 Oct 1;59(19):4919-26
pubmed: 10519405
J Control Release. 2011 May 30;152(1):84-9
pubmed: 21295088
Ann Surg Oncol. 2012 Jul;19(7):2264-71
pubmed: 22350599
Mater Sci Eng C Mater Biol Appl. 2018 Jan 1;82:1-9
pubmed: 29025636
Theranostics. 2019 Oct 17;9(26):8073-8090
pubmed: 31754382